Overview

  • Product name

    Anti-Angiopoietin-like 4/ANGPTL4 antibody
    See all Angiopoietin-like 4/ANGPTL4 primary antibodies
  • Description

    Rabbit polyclonal to Angiopoietin-like 4/ANGPTL4
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human Angiopoietin-like 4/ANGPTL4 (internal sequence).
    (Peptide available as ab123817)

  • Positive control

    • Breast cancer tissue.
  • General notes

     This product was previously labelled as Angiopoietin-like 4

     

Properties

Applications

Our Abpromise guarantee covers the use of ab115798 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.1 - 0.5 µg/ml. Predicted molecular weight: 45 kDa.

The detection limit for Angiopoietin-like 4/ANGPTL4 is approximately 2.5ng/lane under non-reducing and reducing conditions.

Target

  • Function

    Protein with hypoxia-induced expression in endothelial cells. May act as a regulator of angiogenesis and modulate tumorgenesis. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. May exert a protective function on endothelial cells through an endocrine action. It is directly involved in regulating glucose homeostasis, lipid metabolism, and insulin sensitivity. In response to hypoxia, the unprocessed form of the protein accumulates in the subendothelial extracellular matrix (ECM). The matrix-associated and immobilized unprocessed form limits the formation of actin stress fibers and focal contacts in the adhering endothelial cells and inhibits their adhesion. It also decreases motility of endothelial cells and inhibits the sprouting and tube formation.
  • Tissue specificity

    Expressed at high levels in the placenta, heart, liver, muscle, pancreas and lung but expressed poorly in the brain and kidney.
  • Sequence similarities

    Contains 1 fibrinogen C-terminal domain.
  • Post-translational
    modifications

    N-glycosylated.
  • Cellular localization

    Secreted. Secreted > extracellular space > extracellular matrix. The unprocessed form interacts with the extracellular matrix. This may constitute a dynamic reservoir, a regulatory mechanism of the bioavailability of ANGPTL4.
  • Information by UniProt
  • Database links

  • Alternative names

    • Angiopoietin like 4 antibody
    • Angiopoietin related protein 4 antibody
    • Angiopoietin-like protein 4 antibody
    • Angiopoietin-related protein 4 antibody
    • ANGL4_HUMAN antibody
    • ANGPT L2 antibody
    • ANGPT L4 antibody
    • ANGPTL2 antibody
    • Angptl4 antibody
    • ARP4 antibody
    • Fasting induced adipose factor antibody
    • FIAF antibody
    • HARP antibody
    • Hepatic angiopoietin related protein antibody
    • Hepatic fibrinogen/angiopoietin related protein antibody
    • Hepatic fibrinogen/angiopoietin-related protein antibody
    • HFARP antibody
    • NL2 antibody
    • Peroxisome proliferator-activated receptor (PPAR) gamma induced angiopoietin related protein antibody
    • PGAR antibody
    • pp1158 antibody
    • PPARG angiopoietin related protein antibody
    • PSEC0166 antibody
    • TGQTL antibody
    • UNQ171 antibody
    • Weakly similar to angiopoietin 1 [H.sapiens] antibody
    see all

Images

  • All lanes : Anti-Angiopoietin-like 4/ANGPTL4 antibody (ab115798)

    Lane 1 : Human Placenta Tissue Lysate at 50 µg
    Lane 2 : SMMC Whole Cell Lysate at 40 µg
    Lane 3 : HeLa Whole Cell Lysate at 40 µg

    Predicted band size: 45 kDa

  • All lanes : Anti-Angiopoietin-like 4/ANGPTL4 antibody (ab115798)

    Lane 1 : Smmc Whole Cell Lysate
    Lane 2 : A549 Whole Cell Lysate
    Lane 3 : U87 Whole Cell Lysate
    Lane 4 : 293T Whole Cell Lysate
    Lane 5 : SGC Whole Cell Lysate

    Predicted band size: 45 kDa

References

This product has been referenced in:

  • Chellan B  et al. Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype. Sci Rep 8:11954 (2018). Read more (PubMed: 30097618) »
  • Li B  et al. TGF-ß2-induced ANGPTL4 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone. Oncotarget 8:54966-54977 (2017). Read more (PubMed: 28903395) »
See all 3 Publications for this product

Customer reviews and Q&As

Question
Answer

Thank you for contacting us.  We have added the blocking peptide for ab115798 to our catalog.  It is now listed as Angiopoietin-like 4 peptide - ab123817.  The lead time for this peptide is currently 3-4 weeks.  I hope this helps, please let me know if you need any additional assistance. 

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up